UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 4)

NEUROGENE INC.

NEUROGENE INC.
(Name of Issuer)
Common Stock, par value \$0.000001 per share
(Title of Class of Securities)
64135M105
(CUSIP Number)
December 31, 2023
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
⊠ Rule 13d-1(c)
☐ Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP N	o. 64135M10	5			
1	Name of Reporting Person				
	Redmile Group, LLC				
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)				
	(A) 🗆				
	(B) □				
3	SEC Use Only				
4	CITIZENSHIP OR PLACE OF ORGANIZATION				
	Delaware				
		5	Sole Voting Power		
			0		
	IBER OF IARES	6	Shared Voting Power		
BENE	FICIALLY		1,050,304 (1)		
OWNED BY EACH		7	Sole Dispositive Power		
REPORTING			0		
PERSON WITH		8	Shared Dispositive Power		
			1,050,304 ⁽¹⁾		
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON		ENEFICIALLY OWNED BY EACH REPORTING PERSON		
	1,050,304 (1))			
10	, ,		TE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
11	PERCENT OF C	CLASS REPF	RESENTED BY AMOUNT IN ROW (9)		
	8.1% (2)				
12		ORTING PER	RSON (SEE INSTRUCTIONS)		
	IA, OO				
	111,00				

⁽¹⁾ Redmile Group, LLC's beneficial ownership of the Issuer's common stock ("Common Stock") is comprised of (a) 946,897 shares of Common Stock, and (b) 103,407 shares of Common Stock issuable upon exercise of certain warrants to purchase Common Stock (the "Warrants"), in each case, which are owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile Group, LLC ("Redmile"), including Redmile Biopharma Investments I, L.P. The Common Stock and the Warrants may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile. Redmile and Mr. Green (collectively, the "Reporting Persons") each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

⁽²⁾ Percentage based on: (i) 12,823,696 shares of Common Stock outstanding as of December 18, 2023, as reported by the Issuer in its Form 8-K filed with SEC on December 18, 2023 (the "Form 8-K") plus (ii) 103,407 shares of Common Stock issuable upon exercise of the Warrants.

CUSIP N	o. 64135M10	5				
1	Name of Reporting Person					
	Investor C. Constant					
2	Jeremy C. Green Check the Appropriate Box if a Member of a Group (See Instructions)					
_	CHECK THE 71	I I KOI KIAI	E BOX II A INEMBER OF A GROOF (SEE INSTRUCTIONS)			
	(A) \square					
	(B) □					
3	SEC Use On	LY				
4	CITIZENSHIP OR PLACE OF ORGANIZATION					
	United Kingdom					
	United King	5	Sole Voting Power			
NITIN	IDED OF		0 Shared Voting Power			
	IBER OF IARES	6	SHARED VOTING POWER			
BENE	FICIALLY		1,050,304 (3)			
OWNED BY		7	Sole Dispositive Power			
EACH REPORTING						
PERSON WITH		8	Shared Dispositive Power			
			1,050,304 ⁽³⁾			
9	Aggregate A	моинт В	ENEFICIALLY OWNED BY EACH REPORTING PERSON			
	1,050,304 (3))				
10			TE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)			
11	PERCENT OF C	'i ACC REDI	RESENTED BY AMOUNT IN ROW (9)			
	T EXCENT OF C	LASS KEFT	ALSENTED BY AMOUNT IN ROW (7)			
	8.1% (4)					
12	Type of Repo	ORTING PE	RSON (SEE INSTRUCTIONS)			
	IN, HC					
	11,110					

⁽³⁾ Jeremy C. Green's beneficial ownership of Common Stock is comprised of (a) 946,897 shares of Common Stock, and (b) 103,407 shares of Common Stock issuable upon exercise of the Warrants, in each case, which are owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile, including Redmile Biopharma Investments I, L.P. The Common Stock and the Warrants together may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile. The Reporting Persons each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

⁽⁴⁾ Percentage based on (i) 12,823,696 shares of Common Stock outstanding as of December 18, 2023, as reported by the Issuer in its Form 8-K, plus (ii) 103,407 shares of Common Stock issuable upon exercise of the Warrants.

CUSIP N	o. 64135M10	5			
1	Name of Reporting Person				
	Redmile Biopharma Investments I, L.P.				
2			TE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)		
2	CHECK THE A	PPROPRIAI	LE DOX IF A IVIEMBER OF A GROUP (SEE INSTRUCTIONS)		
	(A) \square				
	(B)				
3	SEC Use Only				
4	CITIZENSHIP OR PLACE OF ORGANIZATION				
	Delaware				
		5	Sole Voting Power		
NUMBER OF		6	Shared Voting Power		
SH	IARES		Similar Volling Fower		
	FICIALLY		652,030		
	NED BY	7	Sole Dispositive Power		
	EACH REPORTING				
PERSON WITH		8	Shared Dispositive Power		
9	A A		652,030 Seneficially Owned by Each Reporting Person		
9	AGGREGATE A	AMOUNT E	SENEFICIALLY OWNED BY EACH REPORTING PERSON		
	652,030				
10	Снеск іг тне	Aggrega	ATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)		
11	Percent of Class Represented by Amount in Row (9)				
	(5)				
	5.1% ⁽⁵⁾				
12	Type of Reporting Person (See Instructions)				
	PN				
	± ± 1				

⁽⁵⁾ Percentage based on 12,823,696 shares of Common Stock outstanding as of December 18, 2023, as reported by the Issuer in its Form 8-K.

Item 1.

(a) Name of Issuer

Neurogene Inc.

(b) Address of Issuer's Principal Executive Offices

535 W 24th Street, 5th Floor New York, New York 10011

Item 2.

(a) Names of Persons Filing

Redmile Group, LLC Jeremy C. Green Redmile Biopharma Investments I, L.P.

(b) Address of Principal Business office or, if None, Residence

Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129

Jeremy C. Green c/o Redmile Group, LLC (NY Office) 45 W. 27th Street, Floor 11 New York, NY 10001

Redmile Biopharma Investments I, L.P. c/o Redmile Group, LLC One Letterman Drive Building D, Suite D3-300 The Presidio of San Francisco San Francisco, California 94129

(c) Citizenship

Redmile Group, LLC: Delaware Jeremy C. Green: United Kingdom Redmile Biopharma Investments I, L.P.: Delaware

(d) Title of Class of Securities

Common Stock, par value \$0.000001 per share

(e) CUSIP Number

64135M105

Item 3.	If th	is statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:						
	(a)	☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 780);						
	(b)	\square Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);						
	(c)	☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);						
	(d)	☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);						
	(e)	\square An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);						
	(f)	\square An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);						
	(g)	\square A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);						
	(h)	☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);						
	(i)	\square A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);						
	(j)	☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);						
	(k)	\Box Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:						
Item 4.	Owi	Ownership.						
	(a)	Amount beneficially owned:						
		Redmile Group, LLC – 1,050,304* Jeremy C. Green – 1,050,304* Redmile Biopharma Investments I, L.P. – 652,030						
	(b)	Percent of class:						
		Redmile Group, LLC – 8.1%** Jeremy C. Green – 8.1%** Redmile Biopharma Investments I, L.P. – 5.1%***						
	(c)	Number of shares as to which Redmile Group, LLC has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote:						
		(iii) Sole power to dispose or to direct the disposition of:						
		(iv) Shared power to dispose or to direct the disposition of: 1,050,304*						
		-,,						

Number of shares as to which Jeremy C. Green has:

(i) Sole power to vote or to direct the vote:

0

(ii) Shared power to vote or to direct the vote: 1,050,304*

- (iii) Sole power to dispose or to direct the disposition of:
- (iv) Shared power to dispose or to direct the disposition of: 1,050,304*

Number of shares as to which Redmile Biopharma Investments I, L.P. has:

- (i) Sole power to vote or to direct the vote:
- (ii) Shared power to vote or to direct the vote: 652.030
- (iii) Sole power to dispose or to direct the disposition of:
- (iv) Shared power to dispose or to direct the disposition of: 652,030
- * Redmile's and Jeremy C. Green's beneficial ownership of the Issuer's Common Stock is comprised of (a) 946,897 shares of Common Stock, and (b) 103,407 shares of Common Stock issuable upon exercise of the Warrants, in each case, owned by certain private investment vehicles and/or sub-advised accounts managed by Redmile, including Redmile Biopharma Investments I, L.P. The Common Stock and the Warrants together may be deemed beneficially owned by Redmile as investment manager of such private investment vehicles and/or sub-advised accounts. The reported securities may also be deemed beneficially owned by Jeremy C. Green as the principal of Redmile. Redmile and Mr. Green each disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.
- ** Percentage based on (i) 12,823,696 shares of Common Stock outstanding as of December 18, 2023, as reported by the Issuer in its Form 8-K, plus (ii) 103,407 shares of Common Stock issuable upon exercise of the Warrants.
- *** Percentage based on 12,823,696 shares of Common Stock outstanding as of December 18, 2023, as reported by the Issuer in its Form 8-K.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following \Box

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

N/A.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

See the response to Item 4.

Item 8. Identification and Classification of Members of the Group.

N/A.

Item 9. Notice of Dissolution of Group.

N/A.

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 14, 2024

Redmile Group, LLC

By: /s/ Jeremy C. Green

Name: Jeremy C. Green Title: Managing Member

/s/ Jeremy C. Green

Jeremy C. Green

Redmile Biopharma Investments I, L.P.

By: Redmile Biopharma Investments I (GP), LLC, its general partner

By: Redmile Group, LLC, its managing member

By: /s/ Jeremy C. Green

Name: Jeremy C. Green Title: Managing Member

Joint Filing Agreement

In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the "Schedule 13G") relating to the Common Stock, \$0.000001 par value per share, of Neurogene Inc., which may be deemed necessary pursuant to Regulation 13D or 13G promulgated under the Exchange Act.

The undersigned further agree that each party hereto is responsible for the timely filing of the Schedule 13G, and for the accuracy and completeness of the information concerning such party contained therein; provided, however, that no party is responsible for the accuracy or completeness of the information concerning any other party, unless such party knows or has a reason to believe that such information is inaccurate.

It is understood and agreed that a copy of this Joint Filing Agreement shall be attached as an exhibit to the Schedule 13G, filed on behalf of each of the parties hereto.

IN WITNESS WHEREOF, each of the undersigned has executed this Joint Filing Agreement as of the 14th day of February, 2024.

REDMILE GROUP, LLC

/s/ Jeremy C. Green

Name: Jeremy C. Green Title: Managing Member

/s/ Jeremy C. Green

JEREMY C. GREEN

REDMILE BIOPHARMA INVESTMENTS I, L.P.

By: Redmile Biopharma Investments I (GP), LLC, its general partner

By: Redmile Group, LLC, its managing member

By: /s/ Jeremy C. Green

Name: Jeremy C. Green Title: Managing Member